Staging and Treatment Decisions for Kidney Cancer

Brian Shuch, MD, and Neal Shore, MD, FACS, discuss the staging and treatment of kidney cancer, including when to biopsy and how often to do follow-up imaging.

EP: 1.A Growing Incidence of Renal Masses

EP: 2.Diagnostic Tests for Kidney Cancer

EP: 3.Limitations of Conventional Imaging for Assessing Renal Masses

EP: 4.The Role of a Multidisciplinary Team in Managing Kidney Cancer

Now Viewing

EP: 5.Staging and Treatment Decisions for Kidney Cancer

EP: 6.Advances in Imaging for Kidney Cancer Diagnosis and Management

EP: 7.Overview of Clinical Trials for New Imaging Options for Kidney Cancer

EP: 8.Potential Impact of PET/CT Imaging on Improving Patient Care

Related Videos

Related Content

Advertisement

February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor

Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).

February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke

The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

February 15th 2025

Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

Benjamin P. Saylor

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.

February 7th 2025

Exploring the potential role of ctDNA as a biomarker in kidney cancer

Alan Tan, MD

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.

Published: February 6th 2025 | Updated: February 6th 2025

Neoantigen cancer vaccine shows encouraging activity in ccRCC

Hannah Clarke

At a median follow-up of 40.2 months post-surgery, no patients had experienced a disease recurrence.

Related Content

Advertisement

February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor

Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).

February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke

The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

February 15th 2025

Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

Benjamin P. Saylor

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.

February 7th 2025

Exploring the potential role of ctDNA as a biomarker in kidney cancer

Alan Tan, MD

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.

Published: February 6th 2025 | Updated: February 6th 2025

Neoantigen cancer vaccine shows encouraging activity in ccRCC

Hannah Clarke

At a median follow-up of 40.2 months post-surgery, no patients had experienced a disease recurrence.